Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases.

The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases.

Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.

The company was incorporated in 2017 and is headquartered in Seattle, Washington.